Alzheon CEO Martin Tolar interview with Mornings with Maria, a Fox Business channel featuring anchor Maria Bartiromo alongside a roundtable of rotating industry titans and economic experts discussing major news
Mornings with Maria interview of Alzheon CEO, Martin Tolar, MD, PhD, discussing the implications and controversy surrounding the approval of Biogen’s drug, Aduhelm (aducanumab), and Alzheon’s approach of bringing a safe, effective, and accessible treatment option to patients.
“Our approach is to have a small molecule, we have a pill that actually gets very well into the brain, about 40% compared to about 1% with the antibodies. It’s able to fully block the formation of the toxic form of amyloid and can therefore be used, not only therapeutically, but also preventively.” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon.
Use the outline below to jump to the answers you want to hear within this video interview:
Where are you on this drug at Alzheon? [0:30]
We know that there was a controversy at the FDA over that approval of the Biogen new drug. Three Advisory panel members resigned over the decision. What was the issue, your reaction to the pushback on approving that Biogen drug: [1:36]
So Dr. Tolar, how does it work? The Biogen drug, I know, is attacking the protein plaque amyloid like you said that is on the brain. Is this a similar approach at your company for the drug in Phase 3 trials and do you think that the fact that this Biogen drug did get the approval opens the floodgate to more funding and perhaps Drs sharing information so that we could get to a real treatment and perhaps cure here? How long would that take? [3:18]